Vitamin K occurs in two biologically active forms: phylloquinone (vitamin K1) and menaquinones (vitaminK2). Vitamin K1 is produced by green and leafy vegetables, and algae, whereas vitamin K2 is predominantly of microbial origin. It is Manufactured and sold in India as Mavtrol K2-7, Uni K2-7.
Vitamin K plays a role in the synthesis of hepatic blood coagulation proteins, in bone health, cardiovascular health, prevention of cancer, and suppression of inflammation, prevention of brain oxidative damage, sphingolipid synthesis, and osteoporosis.
The use of Vitamin- K2-7 has been indicated in Coronary Artery Disease with a high risk of CHD for artery calcification.
Dose and Method of Administration
Vitamin K-2-7 is available in two doses; 50 mcg and 100 mcg.
Mode of Action
Matrix-Gla- Protein (MGP), Vitamin K, and Cardiovascular Disease (CVD):
• Among the proteins involved in vascular calcium metabolism, the vitamin K-dependent MGP plays a dominant role.
• MGP is synthesized primarily by chondrocytes and vascular smooth muscle cells and is found in the cartilage, bone, and vasculature.
• MGPs, when carboxylated, play a key role in the inhibition of tissue calcification, thus becoming a very critical factor in plaque formation and reversal.
• Its pivotal importance for vascular health is demonstrated by the fact that there seems to be no effective alternative mechanism for calcification inhibition in the vasculature.
• Inadequate dietary intake of vitamin K may result in under carboxylation of vascular MGP, leading to enhanced calcification of atherosclerotic lesions and, consequently, an increased risk of coronary heart disease.
• Generally, It is recommended that individuals on these medications limit Vitamin K-2-7 consumption to amounts typically found in the average diet (90-120 mcg).
• Pregnant women on warfarin, anticonvulsants, rifampin, or isoniazid place the newborn at increased risk of Vitamin K-2-7 deficiency as these medications can interfere with fetal Vitamin K-2-7 synthesis.
• Extended use of broad-spectrum antibiotics may decrease Vitamin-K2-7 synthesis by intestinal bacteria.
• The use of cephalosporins and salicylates may adversely affect Vitamin-K2-7 recycling by inhibiting vitamin K epoxide reductase.
• Furthermore, absorption of Vitamin-K2-7 may be decreased with the use of drugs such as cholestyramine, colestipol, orlistat, and substances such as mineral oil and the fat substitute, olestra.
• From a large number of clinical trials using dosages over 40 mg/day, there were no reports of side effects associated with any type of hypercoagulable state.
• Both animal and clinical studies support the conclusion that Vitamin-K2-7 has no abnormal hemostatic activity.
• A high intake of menaquinones does not increase thrombosis risk.
• Vitamin K-dependent proteins have a limited number of Gluresidues capable of g-carboxylation per molecule, beyond which there can be no further g-carboxylation or excessive coagulation.
Stability and Storage
Protect from light and moisture. Keep away from children.
Each pack consists of three strips with 10 tablets each.
Long-chain menaquinones have more complex disappearance curves with a long half-life.
. A point of concern is however the potential interference of K vitamins with OAC treatment: individuals taking anticoagulant medications, such as warfarin (coumarins), should consult their doctor before taking Vitamin-K2-7.